DVAX -Bullish RSI Divergence May Signal an Impending Move Higher

2015년 3월 1일

Eddie Gray (CEO) & the rest of Dynavax's "A-Team" are unequivocally committed and, IMO, well in the process of expanding/creating a diversified PL within a first class biotech franchise. I'm a firm believer that management's rigorous approach to drug development in the field of TLR biology and immune system modulation to attack the challenges of infectious and inflammatory diseases and cancer will extract maximum shareholder value over time; hence, also believe that shares are grossly undervalued at current levels. My LT PT is actually $62.79 (not shown on this chart) but have provided several reference points (R-1 - R-5) that I think, eventually, will be achieved. Disclosure: Long via common equity. For reference only & not investment advice.